Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. Both products are being developed in partnership with Merck Serono, a division of Merck KgA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate Kuvan; expectations regarding the Kuvan expanded access program; expectations regarding filings with regulatory agencies; and the development of 6R-BH4 for other indications. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of ongoing clinical trials related to Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities concerning Kuvan; results and timing of current and planned clinical trials of 6R-BH4 for other indications; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual R
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... that a new market research report is available in ... http://www.reportlinker.com/p0369401/Dry-Powder-Inhalation.html ... the growing emphasis on drug self-administration for chronic conditions, ... availability of innovative inhaler device designs - is driving ...
... NEW YORK, Feb. 1, 2011 Reportlinker.com announces ... in its catalogue: Epoetin alfa ... http://www.reportlinker.com/p0366250/Epoetin-alfa---Comprehensive-patent-search.html Eliminate unnecessary risk with ... Pipeline Developer is a regularly updated, professional ...
Cached Medicine Technology:Reportlinker Adds Dry Powder Inhalation 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 3Reportlinker Adds Epoetin alfa - Comprehensive patent search 4
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... As evidence mounts showing the potential health benefits of ... people are taking supplements. And the chemical industry is ... supplements, health effects could deter growth, so the industry ... claims, according to the cover story in Chemical ... of the American Chemical Society. , Melody M. Bomgardner, ...
(Date:4/23/2014)... from the Cancer Science Institute of Singapore (CSI Singapore) ... cancer specific stem cell which causes gastric cancer. This ... for the treatment of this disease and other types ... Chan Shing Leng, Research Assistant Professor at CSI Singapore, ... of a cell surface protein, CD44v8-10, marks gastric cancer ...
(Date:4/23/2014)... Ritalin, may prevent the depletion of self-control, according to ... of the Association for Psychological Science. , Self-control can ... to focus attention on a boring textbook are hard ... for this difficulty: Exerting self-control for a long period ... on subsequent tasks. , "It is as if self-control ...
(Date:4/22/2014)... Government and industry leaders visited the New Jersey ... President Joel S. Bloom for the launch of ... corporation that provides a new model for business ... higher education assets and investment. U.S. Senator Cory ... CEO Joe Taylor, New Jersey Lieutenant Governor Kim ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... a man in critical condition was hospitalized due to septicemic ... in the bloodstream//. Another women from Bernalillo County died last ... the first to die. ,Bite from an infected ... and pets can transmit plague. ,C. Mack Sewell, ...
... has described the criticism of its alleged negligence of ... and principal of NBMCH, Dr J B Saha, said ... ,Yesterday around 200 HIV-positive persons under the banner of ... at NBMCH and alleged that the HIV patients were ...
... A Government official reports, ‘Indonesia hasn’t shared the genetic information ... of disease control and environment, Nyoman Kandun//, at the Indonesian ... considered and discussed by the Government before any public release ... has been used for research purpose. ,A chain ...
... (Indonesia), Mark Snelling, explains about relief operations in earthquake tore ... 5,700 were died and more than a thousand were injured ... even 24 hours here is an eternity – said latest ... collapsed and 200,000 lost their homes. ,The most ...
... researchers at the Oxford have found that high doses of ... doubles the risk of a heart attack if taken in ... Journal study also explains that there was no danger for ... the benefits for patients who depend on it to lead ...
... by killing thousands of rainbow trout.Due to an outbreak, fishes ... case of viral haemorrhagic septicaemia (VHS) attack on wild fish ... the river Ouse in Britain. ,Scottish island of ... industry officials says there is no harm to human beings. ...
Cached Medicine News:Health News:High Doses Of Common Pain killers Can Double The Chances Of Heart attack 2
... DPX Duo is a SmartBeam platform providing ... measurements of the two most clinical sites ... and at a low radiation dose., ... on Windows, optimizes productivity and ensures consistant ...
... the highly respected single-source CT solution, from ... plaque. With its proprietary STRATON X-ray tube, ... of 0.33s, virtually freezing the hearts motion. ... delivers unprecedented diagnostic detail with up to ...
... Blood Pressure Monitoring System (ABPM) allows health ... blood pressure throughout the day. ABPM therapy ... hypertension and the data generated can be ... compact monitor has sophisticated tracking capabilities to ...
... on Philips' iSyntax technology, which uniquely solves ... image data sets using standard desktop PCs, ... new infrastructure is required. iSite Enterprise delivers ... displayed view, making Philips' image delivery method, ...
Medicine Products: